Details of the Drug

General Information of Drug (ID: DM5Z8ID)

• Drug Name: Tabelecleucel
• Synonyms: Tab-cel

Indication

Disease Entry	ICD 11	Status	REF
Post-transplant lymphoproliferative disorder	2B32	Phase 3	[1]
Nasopharyngeal carcinoma	2B6B	Phase 2	[2]

• Drug Type: Cell therapy
• Cross-matching ID:
  UNII: G3NJ7M8N4H
  DrugBank ID: DB17072
  TTD ID: DY4Q6M
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

References

• [1] ClinicalTrials.gov (NCT03394365) Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE). U.S. National Institutes of Health.
• [2] ClinicalTrials.gov (NCT00953420) Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes (CADEN). U.S. National Institutes of Health.